There is growing recognition of the metabolic links between metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia and the need to take these links into account when diagnosing and treating these two diseases. This Review covers connections between MASLD, sarcopenia and metabolic syndrome and discusses how care for patients affected by these diseases is evolving.
- Chang-Hai Liu
- Qing-Min Zeng
- Ming-Hua Zheng